FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, namely to the differential diagnosis of buccal mucosa formation, and can be used in the differential diagnosis of inflammatory diseases and malignant neoplasms of the oral cavity in dental, oncological and surgical hospitals. Method involves sampling oral fluid from a patient and performing enzyme immunoassay on a plate based on monoclonal antibodies, followed by analysis of research results, matrix metalloproteinase 2/matrix metalloproteinase 2 (MMP 2/MMP 2) and matrix metalloproteinase 8/matrix metalloproteinase 8 are selected as biomarkers (MMP 8/MMP 8) and determination of their quantitative content in the oral fluid of the patient. For the quantitative content of the biomarker in the oral fluid of matrix metalloproteinase 2/matrix metalloproteinase 2 (MMP 2/MMP 2), the clinical control group takes the level of 2.32-3.38 ng/ml, and matrix metalloproteinase 8/matrix metalloproteinase 8 (MMP 8/MMP 8) clinical control groups take the level of 61.86-91.40 ng/ml. If the content in the oral fluid of matrix metalloproteinase 2/matrix metalloproteinase 2 (MMP 2/MMP 2) in the amount of 121.26-191.54 ng/ml and matrix metalloproteinase 8/matrix metalloproteinase 8 (MMP 8/MMP 8) in the amount of 33 .78-60.58 ng/ml, then inflammation of the buccal mucosa is diagnosed. If the content of matrix metalloproteinase 2/matrix metalloproteinase 2 (MMP 2/MMP 2) in the amount of 4.98-9.28 ng/ml and matrix metalloproteinase 8/matrix metalloproteinase 8 (MMP 8/MMP 8) in the amount of 1063.96-1600.48 ng/ml, then squamous cell carcinoma of the buccal mucosa is diagnosed when determining dental health, then, based on the results of determining the content of biomarkers in the oral fluid of the patient, the tactics of treating the patient are predicted.
EFFECT: invention provides for achieving a significant increase in the diagnostic accuracy of the differential diagnosis of inflammation and squamous cell carcinoma of the buccal mucosa on the day of the patient's visit, a significant increase in the sensitivity of differential express diagnostics, achieving a high probability of detecting inflammation and squamous cell carcinoma in the patient's body, both in the early stages of the disease and at later stages, as well as a significant simplification of patient preparation within a certain time frame for the collection and storage of diagnostic material.
3 cl, 2 ex
